1523P - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumour DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global phase III study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations

K Nishio,K Sakai,T Seto,M Nishio,M Reck,E.B Garon,C.M Visseren-Grul,R.R Hozak,S.R Wijayawardana,S Enatsu,K Nakagawa

doi:10.1093/annonc/mdz260.045

1523P - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumour DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global phase III study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations

K Nishio, K Sakai + Show 9 more

Open Access

https://doi.org/10.1093/annonc/mdz260.045

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
License type: publisher-specific-oa

Affiliation: Kindai University, National Hospital Organization Kyushu Cancer Center

#Research Grant #Expert Testimony + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1523P - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumour DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global phase III study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations

Full Text